Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013

Ira M. Jacobson, MD

Volume 10, Issue 1, Supplement 1 January 2014

The 64th Annual Meeting of the American Association for the Study of Liver Diseases

November 1-5, 2013 • Washington DC

Special Reporting on:

  • Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection
  • Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection
  • Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations
  • All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV
  • Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in Difficult-to-Treat HCV Infection
  • Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNA

    PLUS Meeting Abstract Summaries

    With Expert Commentary by:

    Ira M. Jacobson, MD

    Weill Cornell Medical College New York, New York

Millennium Medical Publishing, Inc